Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Amortization of Deferred Charges (2016 - 2018)

Historic Amortization of Deferred Charges for Pharma (IGC) over the last 8 years, with Q3 2018 value amounting to $18000.0.

  • Pharma's Amortization of Deferred Charges fell 4267.52% to $18000.0 in Q3 2018 from the same period last year, while for Mar 2019 it was $18000.0, marking a year-over-year change of. This contributed to the annual value of $18000.0 for FY2019, which is N/A changed from last year.
  • Latest data reveals that Pharma reported Amortization of Deferred Charges of $18000.0 as of Q3 2018, which was down 4267.52% from -$115000.0 recorded in Q1 2018.
  • In the past 5 years, Pharma's Amortization of Deferred Charges registered a high of $63616.0 during Q3 2014, and its lowest value of -$115000.0 during Q1 2018.
  • Its 5-year average for Amortization of Deferred Charges is $27604.3, with a median of $34650.0 in 2016.
  • In the last 5 years, Pharma's Amortization of Deferred Charges surged by 35695.43% in 2016 and then crashed by 54571.92% in 2018.
  • Over the past 5 years, Pharma's Amortization of Deferred Charges (Quarter) stood at $55200.0 in 2014, then tumbled by 123.05% to -$12726.0 in 2015, then soared by 356.95% to $32700.0 in 2016, then surged by 43.73% to $47000.0 in 2017, then tumbled by 61.7% to $18000.0 in 2018.
  • Its last three reported values are $18000.0 in Q3 2018, -$115000.0 for Q1 2018, and $47000.0 during Q4 2017.